New CAR-T therapy shows promise for Hard-to-Treat myeloma
NCT ID NCT07139509
First seen Jan 11, 2026 · Last updated May 07, 2026 · Updated 17 times
Summary
This early-stage trial tests a new treatment for adults with multiple myeloma that has come back or not responded to other therapies. The treatment uses immune cells from donated cord blood that are specially designed to target and kill myeloma cells. The main goals are to check the treatment's safety and find the best dose. Eighteen participants will receive the cells after a short course of chemotherapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY MULTIPLE MYELOMA (MM) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Xi'an No.3 Hospital
RECRUITINGXi’an, Shanxi, 710016, China
Conditions
Explore the condition pages connected to this study.